- Scinai Immunotherapeutics Ltd. has signed a five-year Master Service Agreement (MSA) with Ayana Pharma Ltd.
- Under the agreement, Scinai will provide drug development and cGMP manufacturing services to Ayana.
- The deal is expected to generate at least $1.8 million in revenues for Scinai over the next five years.
Scinai Immunotherapeutics Ltd. announced on April 8, 2024, that it has signed a five-year Master Service Agreement (MSA) with Ayana Pharma Ltd. The agreement involves Scinai’s CDMO business unit, Scinai Bioservices, providing drug development and cGMP manufacturing services to Ayana. This includes aseptic filling, quality assurance, and encapsulating drug substances of various partners of Ayana into Ayana’s proprietary liposomal drug delivery system.
Ayana’s COO, Yanir Aldouby, expressed satisfaction with the partnership, stating, “After an extensive search, we are pleased to have selected Scinai Bioservices as our CDMO for our future projects.” Aldouby praised Scinai’s experience in bio-pharmaceutical drug development and manufacturing for clinical trials, their adherence to stringent international regulatory requirements, and their customer responsiveness.
Elad Mark, Scinai’s COO, welcomed Ayana as a client and highlighted their innovative liposomal nano-pharmaceutical products. He stated, “As a biologics CDMO with end-to-end capabilities, we provide personal and professional services to our clients.”
The agreement is anticipated to provide Scinai with at least $1.8 million in revenues over the next five years. Amir Reichman, Scinai’s CEO, sees this contract as a validation of their strategic decision to create two business units, one focused on providing CDMO services and the other on drug development of an innovative pipeline of biologic therapeutic products.
